UPDATE

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933)…

SIGNY, Switzerland--(BUSINESS WIRE)--Fresh data from Global Blue shows the dynamic recovery for Tax Free Shopping has been accelerating across Continental Europe and Asia Pacific. In Continental Europe, issued sales in store like-for-like…

WOODCLIFF LAKE, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023. Highlights: During the 12 months ended September 30,…

FRANKLIN, Tenn., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to bringing access to great healthcare to everyone…

New features improve cloud elasticity/scalability, electrification capabilities, and product development decision-making TROY, Mich., Jan. 9, 2023 /PRNewswire/ -- Altair (Nasdaq: ALTR), a global leader in computational science and…

–   On track to fulfill all elements of Vision 3x3 to build a sustainable, profitable, leading biopharma company COPENHAGEN, Denmark, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided an update on its…

Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023 Recently…

Robust pipeline provides potential for long-term value creation, establishing Sage as a leader in brain health Rolling New Drug Application (NDA) submission for zuranolone in MDD and PPD complete, with potential for PDUFA date as early as…

NEW YORK--(BUSINESS WIRE)--Macy’s, Inc. (NYSE: M) today announced updates to its fiscal fourth quarter sales and adjusted EPS guidance provided on its November 17, 2022 earnings call. Net sales are now expected to be at the low-end to…

Report top-line data from UPLIFT registrational trial in mid-2023, submit potential BLA around year end 2023, and prepare for potential U.S. commercial launch in 2024Advance Phase 3 UP-NEXT and Phase 1 UPGRADE-A trials in…